{
    "clinical_study": {
        "@rank": "26821", 
        "acronym": "Budesonide", 
        "arm_group": [
            {
                "arm_group_label": "Cursurf", 
                "arm_group_type": "No Intervention", 
                "description": "The baby with respiratory distress syndrome was given Cursurf through intubation."
            }, 
            {
                "arm_group_label": "Cursurf and Budesonide", 
                "arm_group_type": "Experimental", 
                "description": "The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation."
            }
        ], 
        "brief_summary": {
            "textblock": "Infants showing high local pulmonary inflammation diagnosted by respiratory distress\n      syndrome usually need the second or more pulmonary surfactant and is easier to developing to\n      Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome,\n      Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is\n      Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of\n      Brochopulmonary dysplasia."
        }, 
        "brief_title": "Curosurf/Budesonide for Infants With Respiratory Distress Syndrome", 
        "condition": "Respiratory Distress Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of respiratory distress syndrome\n\n        Exclusion Criteria:\n\n          -  pneumothorax\n\n          -  surgical disease\n\n          -  major congenical defects"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013115", 
            "org_study_id": "curosurf/Budesonide for NRDS"
        }, 
        "intervention": {
            "arm_group_label": "Cursurf and Budesonide", 
            "description": "Experimental:   Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation", 
            "intervention_name": "Budesonide", 
            "intervention_type": "Drug", 
            "other_name": "Pumicort"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Poractant alfa"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "infant", 
            "respiratory distress syndrome"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "number_of_arms": "2", 
        "official_title": "Curosurf/Budesonide for Infants With Respiratory Distress Syndrome", 
        "other_outcome": {
            "description": "The hypothesis is Cursurf/Budesonide could reduced the need of intubation", 
            "measure": "need of intubation", 
            "safety_issue": "Yes", 
            "time_frame": "one month"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "PR China:Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant", 
            "measure": "need of pulmonary surfactant", 
            "safety_issue": "Yes", 
            "time_frame": "one month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013115"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
            "investigator_full_name": "Chen Long,MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia.", 
            "measure": "the incidence of bronchopulmonary dysplasia", 
            "safety_issue": "Yes", 
            "time_frame": "gestional age 36 weeks or later"
        }, 
        "source": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}